A citation-based method for searching scientific literature

Andre F Batista, Victor Bodart-Santos, Fernanda G De Felice, Sergio T Ferreira. CNS Drugs 2019
Times Cited: 35







List of co-cited articles
437 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
361
31

In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
220
25

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
439
22

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
235
20

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.
Steven E Arnold, Zoe Arvanitakis, Shannon L Macauley-Rambach, Aaron M Koenig, Hoau-Yan Wang, Rexford S Ahima, Suzanne Craft, Sam Gandy, Christoph Buettner, Luke E Stoeckel,[...]. Nat Rev Neurol 2018
552
20


Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
247
20

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
594
17

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
17



The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
478
17

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
291
17

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
262
17

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
601
17


Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.
Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, Maria d'Erme, Susanna Morano, Bruno Maras, Tiziana Filardi. Front Neurosci 2019
74
17

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
172
17



The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
Henrik H Hansen, Katrine Fabricius, Pernille Barkholt, Michael L Niehoff, John E Morley, Jacob Jelsing, Charles Pyke, Lotte Bjerre Knudsen, Susan A Farr, Niels Vrang. J Alzheimers Dis 2015
108
17



Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, Gail Busza, Clive Holmes, Craig Ritchie, Robert Lawrence, Brady McFarlane, George Tadros, Basil H Ridha,[...]. Trials 2019
83
14


Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Suzanne Craft, Laura D Baker, Thomas J Montine, Satoshi Minoshima, G Stennis Watson, Amy Claxton, Matthew Arbuckle, Maureen Callaghan, Elaine Tsai, Stephen R Plymate,[...]. Arch Neurol 2012
842
14

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
Suzanne Craft, Amy Claxton, Laura D Baker, Angela J Hanson, Brenna Cholerton, Emily H Trittschuh, Deborah Dahl, Erin Caulder, Bryan Neth, Thomas J Montine,[...]. J Alzheimers Dis 2017
166
14


Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
Kathleen T Watson, Tonita E Wroolie, Gabby Tong, Lara C Foland-Ross, Sophia Frangou, Manpreet Singh, Roger S McIntyre, Siena Roat-Shumway, Alison Myoraku, Allan L Reiss,[...]. Behav Brain Res 2019
49
14

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
Andre F Batista, Leticia Forny-Germano, Julia R Clarke, Natalia M Lyra E Silva, Jordano Brito-Moreira, Susan E Boehnke, Andrew Winterborn, Brian C Coe, Ann Lablans, Juliana F Vital,[...]. J Pathol 2018
132
14

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Peng Feng, Xiangjian Zhang, Dongfang Li, Chenhui Ji, Ziyue Yuan, Ruifang Wang, Guofang Xue, Guanglai Li, Christian Hölscher. Neuropharmacology 2018
60
14




Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M Sexton, Laurence J Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M Fletcher, Dehua Yang,[...]. Pharmacol Rev 2016
159
14

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
14


Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
199
14


How does brain insulin resistance develop in Alzheimer's disease?
Fernanda G De Felice, Mychael V Lourenco, Sergio T Ferreira. Alzheimers Dement 2014
216
11

Diabetes mellitus and the risk of dementia: The Rotterdam Study.
A Ott, R P Stolk, F van Harskamp, H A Pols, A Hofman, M M Breteler. Neurology 1999
11

Association of diabetes mellitus and dementia: the Rotterdam Study.
A Ott, R P Stolk, A Hofman, F van Harskamp, D E Grobbee, M M Breteler. Diabetologia 1996
469
11

Incretin hormones: Their role in health and disease.
Michael A Nauck, Juris J Meier. Diabetes Obes Metab 2018
262
11

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease.
Sergio T Ferreira, Julia R Clarke, Theresa R Bomfim, Fernanda G De Felice. Alzheimers Dement 2014
225
11

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.
Fernanda G De Felice, Marcelo N N Vieira, Theresa R Bomfim, Helena Decker, Pauline T Velasco, Mary P Lambert, Kirsten L Viola, Wei-Qin Zhao, Sergio T Ferreira, William L Klein. Proc Natl Acad Sci U S A 2009
483
11

Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes.
Na Zhao, Chia-Chen Liu, Alexandra J Van Ingelgom, Yuka A Martens, Cynthia Linares, Joshua A Knight, Meghan M Painter, Patrick M Sullivan, Guojun Bu. Neuron 2017
146
11

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati, Yazhou Li, David Tweedie, Maja Mustapic, Sahil Chawla, Kashfia Chowdhury, Simon S Skene, Nigel H Greig,[...]. JAMA Neurol 2019
112
11

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Chenhui Ji, Guo-Fang Xue, Cao Lijun, Peng Feng, Dongfang Li, Lin Li, Guanglai Li, Christian Hölscher. Brain Res 2016
65
11

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Shuchun Chen, Seong-Jin Yu, Yazhou Li, Daniela Lecca, Elliot Glotfelty, Hee Kyung Kim, Ho-Il Choi, Barry J Hoffer, Nigel H Greig, Dong Seok Kim,[...]. Sci Rep 2018
32
12

Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.